New IBD drug candidate SPH7854 begins first human safety tests
NCT ID NCT06483373
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests the safety of a new drug called SPH7854 in 111 healthy adults. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to see if it is safe enough to test in people with inflammatory bowel disease in future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPH7854 granules
What this could lead to
If safe and well-tolerated, this could pave the way for testing SPH7854 as a potential treatment for inflammatory bowel disease.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and drug processing, not whether the drug works for IBD. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Second University Hospital, Sichuan University
RECRUITINGChengdu, China
Contact